Freenome develops and provides a medical artificial intelligence (AI) platform to detect cancer at its earliest stages. The company utilizes an AI genomics platform and develops noninvasive blood tests to improve precision oncology treatments.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease.

To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. 

We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. 
 
A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.

Roche

Google Ventures

BrightEdge Fund

Soleus Capital

Janus Henderson Investors

Kaiser Permanente Ventures

Roche Venture Fund

Bain Capital Life Sciences

Novartis

Polaris Partners

Section 32 Eventide

Kaiser Permanente

Logos Capital

Andreessen Horowitz

Artis Ventures (AV)

Pura Vida Investments

RA Capital Management

T. Rowe Price

ARK Investment Management

ArrowMark Partners

Sands Capital Ventures

Freenome

What if you could detect lung cancer early through a blood test?

At Freenome, we’ve set out to realize this possibility with our just-initiated PROACT LUNG study. Our goal is to validate the clinical efficacy of our blood test for the early detection of lung cancer.

We will enroll as many as 20,000 current and former smokers over age 50 by collaborating with up to 100 sites across the U.S. This approach aims for geographic and demographic inclusivity, aligning with our commitment to accessible early cancer detection for all. 

Why is this significant? 

Because early detection saves lives. Currently, lung cancer screening rates are low - less than 6% of those eligible were screened based on a 2022 report from the American Lung Association. Our blood test may offer a promising, convenient addition to current screening methods that may encourage more of those eligible to be screened.

Through PROACT LUNG, Freenome is building toward a future where early detection is the norm, not a what-if.

Find the full press release here:
https://lnkd.in/gnDMNMtm

Today, we announce the closure of a $254 million funding round led by Roche alongside existing and new investors. Their strategic investment will accelerate our efforts to advance early cancer detection.

This funding demonstrates our collective commitment to transforming cancer care by helping make early cancer detection "more convenient, accessible and actionable for everyone," in the words of our CEO Mike Nolan.

Detecting cancer too late is contributing to its high mortality rate. This is epitomized by colorectal cancer, which is highly treatable if caught early. At Freenome, we are determined to change this dynamic by integrating computational biology, machine learning, and other technologies to detect cancer early—when it is most treatable.

Learn more:
https://lnkd.in/g_v2zsxN

#Freenome #EarlyCancerDetection #CancerResearch #HealthcareInnovation

According to the American Lung Association, while tobacco use remains the leading risk factor for lung cancer, secondhand smoke, radon, and air pollution also significantly contribute to lung cancer cases.

Our focus at Freenome is to develop innovative blood tests that aid in early detection.

Learn more about our current work in lung cancer early detection:
https://lnkd.in/gnDMNMtm

#earlycancerdetection #multiomics #cancerresearch

The American Lung Association highlights that only 4.5% of high-risk individuals nationally are screened for #LungCancer, with significant variations between states. Massachusetts leads with a rate of 11.9%, while California lags at 0.7%. 

This data demonstrates the need for widespread, effective screening, especially in underserved states. Freenome’s focus is on bridging these screening gaps through innovative, non-invasive testing methods.

#EarlyCancerDetection #CancerScreening #GetScreened

Individuals aged 50-80 years with a history of 20 or more pack-years of smoking are now considered high risk for lung cancer, as per the updated USPSTF guidelines. This broadened criterion has significantly increased the number of people eligible for screening, especially among women and Black Americans.

At Freenome, we recently initiated our PROACT LUNG clinical study for the early detection of lung cancer using a blood test developed on our multiomics platform. With this, we aim to complement current screening and prevention efforts. Our blood tests may help detect lung cancer at its earliest, most treatable stages.

Learn more about PROACT LUNG here:
https://lnkd.in/gNGeBiZb

#EarlyCancerDetection #LungCancer #Multiomics

Dheeraj Talreja, Senior Vice President of Marketing and Commercial Strategy at Freenome, spotlights how community engagement is central to both our approach and our core values at Freenome. As he states, "We all need to come together to tackle the challenges of early cancer detection. Our internal teams, industry peers, advocacy groups, and community partners must address this together. None of us can do it alone. Freenomers demonstrate this attitude every single day, and I couldn't be more excited about being part of this mission."

This philosophy is critical to Freenome's mission. We strive to ensure that our research and product development are rooted in the needs and perspectives of the communities we aim to serve.

#CommunityEngagement #PatientCentric #EarlyCancerDetection

At Freenome we not only have employees that bring technical skill, creative vision, and deep empathy to their work, but in fact, we have a team full of people that represent all of these attributes. It is one of the keys to our continued progress towards the creation of early cancer detection blood tests.

This February, we are observing National Cancer Prevention Month.

Freenome's PROACT Lung and PREEMPT CRC® clinical studies—together involving more than 50,000 participants across 300+ locations—demonstrate our dedication to early cancer detection. To address disparities in cancer diagnosis and survival rates, we have and continue to focus on reaching and representing historically underserved communities.

Discover more about our clinical study program here:
https://lnkd.in/e-26t4N8

#NationalCancerPreventionMonth #EarlyCancerDetection #HealthEquity

At Freenome, we're a values-led organization. We pride ourselves on bringing together employees with diverse experience, expertise, and backgrounds, but who all exhibit the same key traits that make our culture thrive. This is what allows us to build a team greater than the sum of its parts. 

#OrganizationalCulture #Culture #Teamwork

Although there's no straightforward remedy for curing cancer, one fact stands clear: early detection significantly improves our chances of defeating it. 

In the case of colorectal cancer, for instance, early diagnosis leads to a 90% survival rate. While effective screening methods like colonoscopies for colorectal cancer and mammograms for breast cancer are available and proven to save lives, the persistently high cancer mortality rates indicate that not everyone receives timely screenings.

Learn more about the importance of early detection on our website: 

https://lnkd.in/gBGQr3RH

#earlycancerdetection #liquidbiopsy #cancerscreening #cancer

COM:FREENOME

Freenome Holdings Inc

Analysis Not Available